CorestemChemon Advances Toward ALS Stem Cell Commercialization with Regulatory Progress in Korea and NSF-Backed U.S. Expansion

2025.12.18

Neuronata-R® Phase 3 Results Confirm Subgroup Benefit at PACTALS 2025, Strengthening Biomarker-Driven Pathway

2025.09.18

Neuronata-R® Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis, Moves Toward FDA Accelerated Approval

2025.07.21

Neuronata-R(R) Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis, Moves Toward FDA Accelerated Approval

2025.06.09

CorestemChemon Partners with Leading U.S. ALS Patient Association to Promote in North American Market

2024.06.18

CorestemChemon ran in marathon on ALS Awareness Day for the people with ALS

2024.06.03

CorestemChemon Participate in '2024 JP Morgan Healthcare Conference'

2024.02.15

CorestemChemon to Participate in 'BIO Europe 2023'

2024.02.15

"CorestemChemon Invited to Korean-American Pharmaceutical & Bio Union Event to Present Plans for ‘Neuronata-R Phase III Clinical Trial' and 'Non-clinical CRO Business'"

2024.02.15